Abstract
Parenterally administered Dengzhan Xixin is a common parenterally administered Chinese medicine for the treatment of coronary heart disease. The present research explored the application of parenterally administered Dengzhan Xixin on the clinical outcome of coronary disease. Hospital information system (HIS) data from 18 national, general hospitals was collected. Patients given parenterally administered Dengzhan Xixin in addition to other medications were compared with those not receiving it. General boosted method (GBM) and propensity score weighting was used to control for confounding variables between the groups. Logistic regression, and concomitant variable logistic regression of propensity score weighting were used to analyze the balanced confounding variable. Results showed that there was a statistically significant difference between the groups in death rate. The combined application of parenterally administered Dengzhan Xixin can lower the death rate from coronary disease. However, there are still a large amount of unknown confounding variable to take into account and the present research is a retrospective study. Therefore, prospective studies are warranted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
